BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Punganuru SR, Artula V, Zhao W, Rajaei M, Deokar H, Zhang R, Buolamwini JK, Srivenugopal KS, Wang W. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells 2020;9:E1592. [PMID: 32630235 DOI: 10.3390/cells9071592] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Vilar JB, Christmann M, Tomicic MT. Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go? Cancers 2022;14:2416. [DOI: 10.3390/cancers14102416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wang Z, Dai Z, Zheng L, Xu B, Zhang H, Fan F, Zhang X, Liang X, Liu Z, Yang K, Cheng Q. Ferroptosis Activation Scoring Model Assists in Chemotherapeutic Agents’ Selection and Mediates Cross-Talk With Immunocytes in Malignant Glioblastoma. Front Immunol 2022;12:747408. [DOI: 10.3389/fimmu.2021.747408] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Kim D, Kwon W, Park S, Kim W, Park JK, Han JE, Cho GJ, Yun S, Han SH, Kim MO, Ryoo ZY, Choi SK. Anticancer effects of veratramine via the phosphatidylinositol-3-kinase/serine-threonine kinase/mechanistic target of rapamycin and its downstream signaling pathways in human glioblastoma cell lines. Life Sci 2022;288:120170. [PMID: 34826438 DOI: 10.1016/j.lfs.2021.120170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Miles X, Vandevoorde C, Hunter A, Bolcaen J. MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy. Front Oncol 2021;11:703442. [PMID: 34307171 DOI: 10.3389/fonc.2021.703442] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
5 Dymova MA, Kuligina EV, Richter VA. Molecular Mechanisms of Drug Resistance in Glioblastoma. Int J Mol Sci 2021;22:6385. [PMID: 34203727 DOI: 10.3390/ijms22126385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chen Q, Wang W, Chen S, Chen X, Lin Y. miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop. Cell Mol Biol Lett 2021;26:21. [PMID: 34044759 DOI: 10.1186/s11658-021-00266-9] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Chitneni SK, Zhou Z, Watts BE, Zalutsky MR. Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141. Pharmaceuticals (Basel) 2021;14:358. [PMID: 33924734 DOI: 10.3390/ph14040358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang W, Wang X, Rajaei M, Youn JY, Zafar A, Deokar H, Buolamwini JK, Yang J, Foster JH, Zhou J, Zhang R. Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action. Cancers (Basel) 2020;12:E3651. [PMID: 33291373 DOI: 10.3390/cancers12123651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]